EGFR and neoplasm: Beyond anti-EGFR treatments, patients with BRAFV600E tumours were treated with immunotherapy for anti-PD-L1 in the CheckMate 142 clinical trial [32], as it was shown that PD-L1 is upregulated by EGFR activation.